Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era

Target-oriented agents improve metastatic colorectal cancer (mCRC) survival in combination with chemotherapy. However, the majority of patients experience disease progression after first-line treatment and are eligible for second-line approaches. In such a context, antiangiogenic and anti-Epidermal...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Int J Mol Sci
Glavni autori: Giordano, Guido, Parcesepe, Pietro, Bruno, Giuseppina, Piscazzi, Annamaria, Lizzi, Vincenzo, Remo, Andrea, Pancione, Massimo, D’Andrea, Mario Rosario, De Santis, Elena, Coppola, Luigi, Pietrafesa, Michele, Fersini, Alberto, Ambrosi, Antonio, Landriscina, Matteo
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2021
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8307359/
https://ncbi.nlm.nih.gov/pubmed/34299337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22147717
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items